Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL259 Target Snapshot

Melanocortin receptor 4 · SINGLE PROTEIN · Homo sapiens

5,161Compounds
630Assays
20Approved Drugs
7,973.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Melanocortin receptor 4 shows approved-linked disease relevance led by obesity. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P32245. Start with obesity, then reuse UniProt P32245 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with obesity, then reuse UniProt P32245 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
obesity

Melanocortin receptor 4 shows approved-linked disease relevance led by obesity. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with obesity because it currently carries approved-linked support. Linked drugs include SETMELANOTIDE, SETMELANOTIDE ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Melanocortin receptor 4 as ChEMBL target CHEMBL259, mapped to UniProt P32245. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Melanocortin receptor 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL259
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P32245
Melanocortin receptor 4
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Melanocortin receptor 4 is the right protein anchor across sources, using UniProt P32245 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why obesity is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMelanocortin receptor 4
UniProt AccessionP32245
Component TypeProtein
Sequence Length332 aa

Melanocortin receptor 4

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Melanocortin receptor 4, mapped to UniProt P32245. Sequence length is 332 aa.

Mapped IDP32245
Review nameMelanocortin receptor 4
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Melanocortin receptor 4 shows approved-linked disease relevance led by obesity. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
obesity
2 linked drugs · 2 direct · 2 efficacy
Linked drugSETMELANOTIDE
Linked drugSETMELANOTIDE ACETATE
Approved-linked Approved
mental or behavioural disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugBREMELANOTIDE ACETATE
Approved-linked Approved
physiological sexual disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugBREMELANOTIDE ACETATE
Approved-linked Approved
sexual dysfunction
1 linked drug · 1 direct · 1 efficacy
Linked drugBREMELANOTIDE ACETATE
Late clinical Phase III
sexual dysfunction
2 linked drugs · 2 direct · 2 efficacy
Linked drugBREMELANOTIDE
Linked drugPF-00446687
Late clinical Phase III
Bardet-Biedl syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugSETMELANOTIDE
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with obesity because it currently carries approved-linked support. Linked drugs include SETMELANOTIDE, SETMELANOTIDE ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseobesity
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

20
Approved
4
Phase II
Assay Mix

Activity Type Distribution

IC502,232.0
KI3,640.0
EC502,070.0
KD31.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4798971 10.82 Ki 0.015 Preclinical
CHEMBL4794168 10.8 Ki 0.01585 Preclinical
CHEMBL4794121 10.78 Ki 0.0166 Preclinical
CHEMBL441738 10.77 EC50 0.017 Approved
CHEMBL413212 10.74 EC50 0.018 Preclinical
CHEMBL428615 10.72 EC50 0.019 Preclinical
CHEMBL4777048 10.71 Ki 0.0195 Preclinical
CHEMBL4793821 10.68 Ki 0.02089 Preclinical
CHEMBL4788071 10.68 Ki 0.021 Preclinical
CHEMBL4794990 10.59 Ki 0.0257 Preclinical
Distribution

pChEMBL Value Distribution

325
5.0
395
5.5
596
6.0
776
6.5
868
7.0
748
7.5
771
8.0
462
8.5
280
9.0
97
9.5
pChEMBL
Approved Drugs

Approved Drugs

SETMELANOTIDE
CHEMBL3301624
Approved 2020
BREMELANOTIDE
CHEMBL2070241
Approved 2019
AFAMELANOTIDE
CHEMBL441738
Approved 2014
COSYNTROPIN
CHEMBL2103784
Approved 1970
Assay Landscape

Assay Landscape

630
Total Assays
3,011
Tested Compounds
3
Assay Types
Binding — 336 assays, 3,011 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 175 2,139 7.2
single protein format 148 530 7.3
assay format 7 264 7.1
cell membrane format 6 78 7.8
Functional — 288 assays, 1,389 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 217 968 7.3
assay format 68 395 7.3
single protein format 2 0
cell membrane format 1 26 8.8
ADME — 6 assays, 12 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 6 12 7.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine